PRINCETON, N.J., Oct. 28, 2005 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long-term growth and income-generating focused online investment newsletter, announced today that it has provided subscribers with a detailed look at various companies in the healthcare arena including Amgen (Nasdaq:AMGN), Invacare (NYSE:IVC), Zimmer Holdings (NYSE:ZMH), and Aetna (NYSE:AET). Coverage on additional healthcare-related stocks can also be found in The Bull Market Report Archives and in upcoming issues.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to The Bull Market Report's exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR53
In examining Amgen's pipeline, The BullMarket Report wrote: "The two most exciting drugs Amgen has in development are denosumab (formerly AMG 162) for the treatment of osteoporosis and cancer drug panitumumab. Analysts consider denosumab the company's strongest pipeline candidate to become the next blockbuster. Data from a number of studies indicate that it could have a range of applications because it works quickly, has a long duration, and it has a very encouraging safety profile."
In its coverage, The Bull Market Report looked at the following topics, among many others:
-- Why does The Bull Market Report think Amgen's drug pipeline
could be a strength for the firm, even though it has often
been cited as a weakness by analysts?
-- After a big drop following its earnings, does Invacare
have enough positives going for it to warrant an investment?
-- Near multi-year lows, does Zimmer Holdings look like a
turnaround play?
-- Despite slowing growth throughout the health insurance
industry, why is The Bull Market Report still bullish on
Aetna?
About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. Start your 14-day free trial today:
https://www.bullmarket.com/subscribe/?refer=BMR53
Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook," "Biotech Sector Outlook," and "Understanding the Value of Insider Trading Data."
Note: This release was published by F.P. Real Ventures I, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.